Needham & Co. Raises PT on Cantel Medical (CMN) to $33

Following the company's positive earnings report yesterday, Needham & Company maintained a Buy rating on Cantel Medical (NYSE: CMN) and raised its price target to $33.00 (from $28.00).

Commenting on the results, analyst Dalton Chandler said, "CMN slightly missed our revenue estimate, but emphasis on new, higher margin products and focus on cost controls helped the company easily top our bottom line estimate. These improvements appear to be sustainable and could improve further."

For an analyst ratings summary and ratings history on Cantel Medical (NYSE: CMN) click here. For more ratings news on Cantel Medical click here.

Shares of Cantel Medical closed at $28.51 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
• European stocks rise, helped by positive global sentiment; NatWest gains
• Alphabet stock soars 12% to record high on Q1 earnings beat, first-ever dividend